DBV Technologies

DBV Technologies ROA

The Return on Assets (ROA) of DBV Technologies (DBVT) as of Nov 15, 2026 is -56.96 %. In the previous year, Return on Assets (ROA) was -173.20 % — a change of -67.11% (higher).

ROA

-56.96 %

YoY

-67.11%

Last updated:

In 2025, DBV Technologies's return on assets (ROA) was -56.96 %, a -67.11% increase from the -173.20 % ROA in the previous year.

The DBV Technologies ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-81.05 USD
Jan 1, 2019
-63.30 USD
Jan 1, 2020
-58.61 USD
Jan 1, 2021
-66.84 USD
Jan 1, 2022
-39.05 USD
Jan 1, 2023
-39.74 USD
Jan 1, 2024
-173.20 USD
Jan 1, 2025
-56.96 USD
The DBV Technologies ROA history
YEARROAYoY
-56.96 %-67.11%
-173.20 %+335.78%
-39.74 %+1.77%
-39.05 %-41.58%
-66.84 %+14.06%
-58.61 %-7.42%
-63.30 %-21.89%
-81.05 %+14.47%
-70.80 %+77.72%
-39.84 %+236.25%
-11.85 %-19.31%
-14.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DBV Technologies Stock analysis

What does DBV Technologies do? DBV Technologies S.A. generates revenue through its clinical-stage biopharmaceutical products, primarily Viaskin Peanut and Viaskin Milk, which are in Phase 3 and Phase 1/2 trials respectively for treating peanut and cow's milk allergies. The company also develops the Viaskin technology platform for food allergy treatment and collaborates with Nestlé Health Science on MAG1C, a diagnostic patch for non-IgE mediated CMPA in infants. Revenue streams include product development partnerships, such as the collaboration with Nestlé Health Science, and potential future sales of approved therapies targeting allergic conditions. The primary buyers of DBV's products and technology are healthcare providers, hospitals, and allergy specialists who treat patients with IgE-mediated allergies and eosinophilic esophagitis. The company's focus on pediatric and adult allergy markets, particularly for peanut and milk allergies, positions it to serve patients requiring immunotherapy solutions. Additionally, diagnostic tools like MAG1C target healthcare professionals involved in early allergy diagnosis for infants and toddlers. DBV Technologies operates within the biopharmaceutical sector, specializing in epicutaneous immunotherapy for food allergies. Its product pipeline includes Viaskin Peanut for peanut allergy treatment, Viaskin Milk for cow's milk allergy, and Viaskin technology for broader food allergy applications. The company's collaboration with Nestlé Health Science on MAG1C represents a strategic partnership to expand diagnostic capabilities in pediatric allergy care, aligning with its research focus on IgE-mediated conditions and eosinophilic esophagitis. DBV Technologies is one of the most popular companies on Eulerpool.

ROA Details

Understanding DBV Technologies's Return on Assets (ROA)

DBV Technologies's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing DBV Technologies's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider DBV Technologies's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in DBV Technologies’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about DBV Technologies stock

Return on Assets (ROA) of DBV Technologies is -56.96 % in 2025.

Return on Assets (ROA) of DBV Technologies changed from -173.20 % to -56.96 %, representing a -67.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) DBV Technologies since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s DBV Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — DBV Technologies

All Key Metrics — DBV Technologies